REGγ, a proteasome activator and beyond?

被引：122

作者：

Mao I. ^{[1
,2
]}

Liu J. ^{[1
]}

Li X. ^{[1
]}

Luo H. ^{[2
]}

机构：

[1] Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai 200241

[2] Department of Pathology and Laboratory Medicine, University of British Columbia, St. Paul's Hospital, Vancouver

来源：

Cellular and Molecular Life Sciences | 2008年 / 65卷 / 24期

关键词：

Cancer; p21; p53; Proteasome activator; REGγ; SRC-3; Ubiquitin- and ATP-independent protein degradation; Viral pathogenesis;

D O I：

10.1007/s00018-008-8291-z

中图分类号：

学科分类号：

摘要：

REGγ, a member of the 11S proteasome activators, has been shown to bind and activate the 20S proteasome to promote proteasome-dependent degradation of important regulatory proteins, such as SRC-3 and cyclin-dependent kinase inhibitors p21, p16, and p19, in a ubiquitin- and ATP-independent manner. Furthermore, REGγ has been shown to facilitate the turnover of tumor suppressor p53 by promoting MDM2-mediated p53 ubiquitination. The discovery that REGγ regulates cell-cycle regulators is consistent with previous studies where REGγ-deficient mice have shown retardation in body growth, decreased cell proliferation and increased apoptosis, indicating a potential role of REGγ in cancer development. Additionally, REGγ's ability to promote viral protein degradation suggests its involvement in viral pathogenesis. This review presents an overview of the function of REGγ, a summary of the current literature, and insight into the possible biological function of REGγ relating to cancer, viral pathogenesis, and other diseases. © 2008 Birkhäuser Verlag.

引用

页码：3971 / 3980

页数：9

共 78 条

[71]

Weekes J., Morrison K., Mullen A., Wait R., Barton P., Dunn M.J., Hyperubiquitination of proteins in dilated cardiomyopathy, Proteomics, 3, pp. 208-216, (2003)

[72]

Hedhli N., Wang L., Wang Q., Rashed E., Tian Y., Sui X., Madura K., Depre C., Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22, Cardiovasc. Res, 77, pp. 497-505, (2008)

[73]

Meiners S., Dreger H., Fechner M., Bieler S., Rother W., Gunther C., Baumann G., Stangl V., Stangl K., Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system, Hypertension, 51, pp. 302-308, (2008)

[74]

Stansfield W.E., Tang R.H., Moss N.C., Baldwin A.S., Willis M.S., Selzman C.H., Proteasome inhibition promotes regression of left ventricular hypertrophy, Am J Physiol. Heart Circ. Physiol, 294, (2008)

[75]

Depre C., Wang Q., Yan L., Hedhli N., Peter P., Chen L., Hong C., Hittinger L., Ghaleh B., Sadoshima J., Vatner D.E., Vatner S.F., Madura K., Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy, Circulation, 114, pp. 1821-1828, (2006)

[76]

Heineke J., Molkentin J.D., Regulation of cardiac hypertrophy by intracellular signalling pathways, Nat. Rev. Mol. Cell Biol, 7, pp. 589-600, (2006)

[77]

Feingold K., Kim M.S., Shigenaga J., Moser A., Grunfeld C., Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response, Am. J. Physiol. Endocrinol. Metab, 286, (2004)

[78]

Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., Akazawa H., Tateno K., Kayama Y., Harada M., Shimizu I., Asahara T., Hamada H., Tomita S., Molkentin J.D., Zou Y., Komuro I., p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload, Nature, 446, pp. 444-448, (2007)

← 1 2 3 4 5 6 7 8 →